Concurrent Effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp Genetic Polymorphisms with Risk of Cancer, Clinical Output, and Response to Treatment with Imatinib Mesylate in Patients with Chronic Myeloid Leukemia

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2015 Aug 8

PMID 26250462

Citations 13

Authors

Hana Salimizand

Sabrieh Amini

Mohammad Abdi

Bayazid Ghaderi

Namam-Ali Azadi

Affiliations

Soon will be listed here.

Abstract

There are a paucity and contradicted data about the impact of concurrent heredity of polymorphic genes and risk of chronic myeloid leukemia (CML). In the present study, the concurrent effects of three polymorphisms affecting the integrity of DNA consist of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp on development of chronic myeloid leukemia were studied. Furthermore, the role of these polymorphisms in clinical and laboratory outcomes of patients was evaluated. In this case-control study, 70 CML patients and 140 healthy individuals were enrolled in the study. The clinical features of patients such as phase of disease and response to treatment and laboratory data before and after treatment with imatinib mesylate were collected. ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp single nucleotide polymorphisms were evaluated by restriction fragment length polymorphism-polymerase chain reaction. The T allele of ABCB1 C3435T, T allele of XRCC1 Arg194Trp, and C allele of ABCG2 C421A polymorphisms were significantly higher in patients than controls. TT genotype of ABCB1 and TT genotype of XRCC1 were associated with higher risk of chronic myeloid leukemia development. CC421 ABCG2/TT3435 ABCB1 and CC421 ABCG2/TT27157 XRCC1 were also correlated with a higher risk of CML. Patients with C allele of ABCB1 had poor cytogenetic response, and correlation of CC421 ABCG2/TT3435 ABCB1 diplotype with accelerated phase of CML was significant. Patients with CC421 ABCG2/TT3435 ABCB1 and CC421 ABCG2/TT27157 XRCC1 diplotypes might be at higher risk to rapid and severe development of CML and have weaker response to treatments with imatinib.

Citing Articles

Impact of Genetic Variants in ABCG2 , NR1I2 , and UGT1A1 on the Pharmacokinetics of Dolutegravir in Children.

Spector S, Brummel S, Chang A, Wiznia A, Ruel T, Acosta E J Acquir Immune Defic Syndr. 2024; 95(3):297-303.

PMID: 38180896 PMC: 10922521. DOI: 10.1097/QAI.0000000000003358.

Association of ABCG2 Polymorphisms on Triple Negative Breast Cancer (TNBC) Susceptibility Risk.

Hao Ing Y, Md Salleh M, Yahya M, Ankathil R, Abdul Aziz A Asian Pac J Cancer Prev. 2023; 24(11):3891-3897.

PMID: 38019248 PMC: 10772757. DOI: 10.31557/APJCP.2023.24.11.3891.

Genetic Variants of ABC and SLC Transporter Genes and Chronic Myeloid Leukaemia: Impact on Susceptibility and Prognosis.

Alves R, Goncalves A, Jorge J, Marques G, Ribeiro A, Tenreiro R Int J Mol Sci. 2022; 23(17).

PMID: 36077209 PMC: 9456284. DOI: 10.3390/ijms23179815.

Imatinib Efficacy, Safety and Resistance in Iranian Patients with Chronic Myeloid Leukemia: A Review of Literature.

Amouei A, Daeian N, Khezrnia S, Mansouri A, Hadjibabaie M Int J Hematol Oncol Stem Cell Res. 2021; 15(2):114-131.

PMID: 34466210 PMC: 8381106. DOI: 10.18502/ijhoscr.v15i2.6042.

DNA Repair Genes and Chronic Myeloid Leukemia: ERCC2 (751), XRCC1 (399), XRCC4-Intron 3, XRCC4 (-1394) Gene Polymorphisms.

Ozdilli K, Pehlivan M, Serin I, Savran F, Tomatir A, Pehlivan S Mediterr J Hematol Infect Dis. 2021; 13(1):e2021020.

PMID: 33747401 PMC: 7938920. DOI: 10.4084/MJHID.2021.020.

References

Andersen V, Ostergaard M, Christensen J, Overvad K, Tjonneland A, Vogel U . Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. BMC Cancer. 2009; 9:407. PMC: 2797527. DOI: 10.1186/1471-2407-9-407. View

Illmer T, Schuler U, Thiede C, Schwarz U, Kim R, Gotthard S . MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res. 2002; 62(17):4955-62. View

Chen P, Zhao L, Zou P, Xu H, Lu A, Zhao P . The contribution of the ABCG2 C421A polymorphism to cancer susceptibility: a meta-analysis of the current literature. BMC Cancer. 2012; 12:383. PMC: 3488524. DOI: 10.1186/1471-2407-12-383. View

Xue H, Ni P, Lin B, Xu H, Huang G . X-ray repair cross-complementing group 1 (XRCC1) genetic polymorphisms and gastric cancer risk: A HuGE review and meta-analysis. Am J Epidemiol. 2011; 173(4):363-75. DOI: 10.1093/aje/kwq378. View

Elghannam D, Ibrahim L, Ebrahim M, Azmy E, Hakem H . Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients. Hematology. 2013; 19(3):123-8. DOI: 10.1179/1607845413Y.0000000102. View

Lee J, Ward W, Liu J, Ren H, Vallanat B, Delker D . Hepatic xenobiotic metabolizing enzyme and transporter gene expression through the life stages of the mouse. PLoS One. 2011; 6(9):e24381. PMC: 3169610. DOI: 10.1371/journal.pone.0024381. View

Benderra Z, Faussat A, Sayada L, Perrot J, Chaoui D, Marie J . Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res. 2004; 10(23):7896-902. DOI: 10.1158/1078-0432.CCR-04-0795. View

Muller P, Asher N, Heled M, Cohen S, Risch A, Rund D . Polymorphisms in transporter and phase II metabolism genes as potential modifiers of the predisposition to and treatment outcome of de novo acute myeloid leukemia in Israeli ethnic groups. Leuk Res. 2008; 32(6):919-29. DOI: 10.1016/j.leukres.2007.10.011. View

Li Y, Wang Y, Li Y, Yang L . MDR1 gene polymorphisms and clinical relevance. Yi Chuan Xue Bao. 2006; 33(2):93-104. DOI: 10.1016/S0379-4172(06)60027-9. View

10.

Keskitalo J, Zolk O, Fromm M, Kurkinen K, Neuvonen P, Niemi M . ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2009; 86(2):197-203. DOI: 10.1038/clpt.2009.79. View

11.

Liu J, Song B, Wang Z, Song X, Shi Y, Zheng J . DNA repair gene XRCC1 polymorphisms and non-Hodgkin lymphoma risk in a Chinese population. Cancer Genet Cytogenet. 2009; 191(2):67-72. DOI: 10.1016/j.cancergencyto.2009.01.015. View

12.

Ioannidis J . Genetic associations: false or true?. Trends Mol Med. 2003; 9(4):135-8. DOI: 10.1016/s1471-4914(03)00030-3. View

13.

Batar B, Guven M, Baris S, Celkan T, Yildiz I . DNA repair gene XPD and XRCC1 polymorphisms and the risk of childhood acute lymphoblastic leukemia. Leuk Res. 2008; 33(6):759-63. DOI: 10.1016/j.leukres.2008.11.005. View

14.

El Mesallamy H, Rashed W, Hamdy N, Hamdy N . High-dose methotrexate in Egyptian pediatric acute lymphoblastic leukemia: the impact of ABCG2 C421A genetic polymorphism on plasma levels, what is next?. J Cancer Res Clin Oncol. 2014; 140(8):1359-65. DOI: 10.1007/s00432-014-1670-y. View

15.

Korenaga Y, Naito K, Okayama N, Hirata H, Suehiro Y, Hamanaka Y . Association of the BCRP C421A polymorphism with nonpapillary renal cell carcinoma. Int J Cancer. 2005; 117(3):431-4. DOI: 10.1002/ijc.21187. View

16.

Woodward O, Kottgen A, Coresh J, Boerwinkle E, Guggino W, Kottgen M . Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci U S A. 2009; 106(25):10338-42. PMC: 2700910. DOI: 10.1073/pnas.0901249106. View

17.

Belitsky G, Yakubovskaya M . Genetic polymorphism and variability of chemical carcinogenesis. Biochemistry (Mosc). 2008; 73(5):543-54. DOI: 10.1134/s0006297908050076. View

18.

Lindahl T, Wood R . Quality control by DNA repair. Science. 1999; 286(5446):1897-905. DOI: 10.1126/science.286.5446.1897. View

19.

Meza-Espinoza J, Peralta-Leal V, Gutierrez-Angulo M, Macias-Gomez N, Ayala-Madrigal M, Barros-Nunez P . XRCC1 polymorphisms and haplotypes in Mexican patients with acute lymphoblastic leukemia. Genet Mol Res. 2009; 8(4):1451-8. DOI: 10.4238/vol8-4gmr687. View

20.

Seedhouse C, Russell N . Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia. Br J Haematol. 2007; 137(6):513-29. DOI: 10.1111/j.1365-2141.2007.06613.x. View